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Huiyu Zhuang, Mingzi Tan, Juanjuan Liu, Zhenhua Hu, Dawo Liu, Jian Gao, Liancheng Zhu and Bei Lin*Abstract
Background: The objective of the present study was to identify human epididymis protein 4 (HE4) interacting
proteins and explore the mechanisms underlying their effect on ovarian cancer cell invasion and metastasis.
Methods: HE4 interacting proteins were identified by mass spectrometry and validated by co-immunoprecipitation
and pull-down assays. The scratch test, the Transwell assay and animal experiments were used to assess the invasive
and metastatic abilities of ovarian cancer cells before and after transfection and HE4 protein treatment. HE4 and
annexin II protein expression in epithelial ovarian tissues was detected by immunohistochemistry, and the relation
between their expression levels was examined.
Results: Annexin II was identified as an HE4 interacting protein. HE4 and annexin II binding interaction promoted
ovarian cancer cell invasion and metastasis. HE4 and annexin II expression levels were significantly higher in
malignant epithelial ovarian tissues than in benign and normal epithelial ovarian tissues, and they were higher in
tissues with lymph node metastases than in those without. HE4 gene interference downregulated the expression of
MAPK and the FOCAL adhesion signaling pathway-associated molecules MKNK2 and LAMB2, and HE4 protein
supplementation reversed this effect.
Conclusion: The binding interaction between HE4 and annexin II activates the MAPK and FOCAL adhesion
signaling pathways, promoting ovarian cancer cell invasion and metastasis.
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Ovarian cancer ranks third among malignant tumors of
the female reproductive system; however, it is the lead-
ing cause of cancer-related mortality, which seriously
threatens women’s lives and health [1,2]. Metastasis and
invasion of early-stage ovarian cancer is a major factor
responsible for its high mortality and poor prognosis.
Therefore, elucidating the mechanisms underlying the
development and progression of ovarian cancer at a mo-
lecular level is important to facilitate the early diagnosis
and treatment of ovarian cancer and to improve the
prognosis of patients with this disease.* Correspondence: linbei88@hotmail.com
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unless otherwise stated.Human epididymis protein 4 (HE4), also known as
whey acidic protein, was first shown to be highly
expressed in ovarian cancer in 1999 [3], and it was iden-
tified as a serum marker for ovarian cancer in 2003 [4].
HE4 is highly expressed in epithelial ovarian cancer,
whereas it is present at low levels in normal tissues,
tumor-adjacent tissues and benign tumors [3,5]. HE4
has higher sensitivity, specificity, positive likelihood ratio
and negative likelihood ratio than CA125 for the diagno-
sis of ovarian cancer [6]. As a secreted glycoprotein [7],
HE4 has a significantly lower molecular weight than
CA125, which has received wide attention. However, lit-
tle is known about the function of HE4, specifically the
role of HE4 in the malignant biological behavior of ovar-
ian cancer. Recent studies showed that HE4 mainly af-
fects the invasive and metastatic ability of ovarian cancer
cells [8,9]; however, the underlying mechanism remainsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with a receptor on the cell membrane to affect the malig-
nant biological behavior of ovarian cancer cells remains
unknown.
In the present study, we showed that annexin II
(ANXA2), a specific binding partner of HE4, is expressed in
ovarian cancer cells, and the interaction between HE4 and
ANXA2 promotes the invasion and metastasis of ovarian
cancer cells via the MAPK and FOCAL signaling pathways.Figure 1 Identification of HE4-interacting proteins. A, The sample was i
blue-stained. Lane 1, marker band. Lane 2, sample band. Lane 3, IgG band. Th
Mascot score by mass spectrometric analysis. The molecular weight of this pro
the proteins pulled down with HE4. C, mass spectrometric analysis of the ban
substrates for HE4.Results
Identification of binding proteins with HE4
To identify specific HE4 binding proteins, co-immunop-
recipitation assays were performed in the ovarian cancer
cell line OVCAR-3. Proteins co-immunoprecipitating with
HE4 were separated by electrophoresis and detected by
Coomassie brilliant blue staining (Figure 1A). Protein
bands were analyzed by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-mmunoprecipitated using an anti-HE4 antibody and Coomassie brilliant
e asterisk indicated that the protein band was the one with the highest
tein is 31KD. Band H means HE4. B, A comprehensive table showing all
d obtained by immunoprecipitation showed different putative binding
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as the band with the highest Mascot score. Binding be-
tween HE4 and ANXA2 was validated via in vivo and
in vitro experiments. Firstly, OVCAR-3, ES-2 and CaoV-3
ovarian cancer cells lysates were precipitated with anti-
bodies specific to HE4 and ANXA2, and the structures of
ANXA2 and HE4 in ovarian cancer cells were examined.
The results of these experiments shown in Figure 2 dem-
onstrate that HE4 and annexin II form a complex that can
be precipitated with either anti-HE4 or anti-annexin II
antibodies and detected by Western blot with anti-
annexin II (Figure 2A) or anti-HE4 (Figure 2B) antibodies,
respectively. To determine the distribution of HE4 and
ANXA2 in ES-2 and CaoV-3 ovarian cancer cells, mem-
brane and cytoplasmic proteins were isolated and sub-
jected to co-immunoprecipitation analysis. The results
showed the presence of HE4 and ANXA2 in the mem-
brane and plasma and confirmed that they are binding
partners (Figure 2C, D).
As a calcium-dependent phospholipid binding protein,
ANXA2 is mainly involved in cell proliferation, adhesionFigure 2 Interaction of HE4 and recombinant annexin II proteins. A, im
and Western blot analysis with anti-annexin II antibody. Lanes 1and 2, control
OVCAR-3, ES-2, CaoV-3. IB, immunoblotting. B, immunoprecipitation of annexi
with anti- HE4 antibody. Lanes 1 and 2, control proteins; lanes 3, 4 and 5, IP b
Lane6, negative control (Ig G). C, IP of membrane and cytoplasmic proteins b
antibody. Lanes 1 and 2, membrane proteins of ovarian cancer cells ES-2 and
membrane and cytoplasmic proteins by anti-annexin II antibody and Western
ovarian cancer cells ES-2 and CaoV-3. Lanes 3 and 4, cytoplasmic proteins of ES
annexin II mutants, A2-del15 and A2-del26, to GST-HE4. Complexes were immu
with anti-His-tagged antibody. Full-size annexin II was used in lanes 1, A2-del15
under the panel mean antibodies used.and signal transduction [10]. However, the effect of HE4
and ANXA2 binding on the malignant biological behav-
iors of ovarian cancer cells remains unclear. Further
studies were carried out to investigate the role of HE4 in
ovarian cancer cells.
Binding of HE4 to recombinant annexin II and
identification of the binding region in the annexin II
molecule
To further identify the binding site between HE4 and
ANXA2, fusion proteins containing glutathione-S-
transferase (GST) and His tags were constructed. To
examine whether the N-terminal region is involved in
the annexin II binding to HE4, two truncated forms of
ANXA2 were produced, A2-del15, which lacked the
first 15 amino acids at the N terminus, and A2-del26,
with an additional deletion of 11 amino acids. Co-
immunoprecipitation assays showed reduced binding of
the mutants A2-del15 and A2-del26 to HE4 (Figure 2E),
indicating that the HE4 and ANXA2 binding site is lo-
cated after the 26th amino acid at the N terminus.munoprecipitation (IP) of annexin II/HE4 complex by anti-HE4 antibody
proteins; lanes 3, 4 and 5, IP by anti-HE4 antibody in ovarian cancer cells
n II/ HE4 complex by anti-annexin II antibody and Western blot analysis
y anti-annexin II antibody in ovarian cancer cells OVCAR-3, ES-2, CaoV-3.
y anti-HE4 antibody and Western blot analysis with anti-annexin II
CaoV-3. Lanes 3 and 4, cytoplasmic proteins of ES-2 and CaoV-3. D, IP of
blot analysis with anti-HE4 antibody. Lanes 1 and 2, membrane proteins of
-2 and CaoV-3. Lane 5, negative control (Ig G). E, binding of truncated
noprecipitated by anti-HE4 antibody , followed by Western blot analysis
was used in lanes 2, and A2-del26 was used in lanes 3. All the plus sign
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expression
ES-2 and CaoV-3 ovarian cancer cells were transfected
with HE4 using gene transfection techniques to generate
the stably transfected cell lines ES-2-HE4-H, ES-2-HE4-L,
CaoV-3-HE4-H and CaoV-3- HE4-L with high and low
HE4 gene and protein expression. HE4 and ANXA2 pro-
tein levels were increased in ES-2-HE4-H and CaoV-3-
HE4-H cells, as detected by western blotting (Figure 3A),
whereas HE4 and ANXA2 were downregulated in ES-2-
HE4-L and CaoV-3-HE4-L cells (P <0.05; Figure 3B). The
results of real-time PCR showed that the up- and down-
regulation of HE4 expression were correlated with alter-
ations of ANXA2 gene expression (P <0.05; Figure 3C).
The results of ELISA showed that HE4 secretion levels
were upregulated after its stable overexpression in the
CaoV-3 cell line (see Additional file 1, P < 0.05). Immuno-
cytochemistry results were consistent with those of west-
ern blot analysis (Figure 3D). HE4 was detected as brown
or pale yellow granules and localized predominantly to the
cytoplasm of ovarian cancer cells, although membrane
and peri-nuclear staining were also observed. ANXA2 ex-
pression was detected in the membrane and cytoplasm of
ovarian cancer cells. Immunocytochemistry results con-
firmed that changes in the expression of HE4 were corre-
lated with those of ANXA2 (see Additional file 2, P <0.05).
Confocal laser scanning microscopy showed the co-
localization of the HE4 and ANXA2 in the two ovarian
cancer cell lines ES-2 and CaoV-3 (some results are not
shown). As shown in Figure 3E, HE4 and ANXA2 mainly
co-localized in the membrane and cytoplasm of CaoV-3
cells, and the intensity of the yellow fluorescence gener-
ated by the co-localization of the HE4 and ANXA2 pro-
teins significantly decreased with the reduced HE4
expression (P <0.05). These results indicate that downreg-
ulation of HE4 decreases HE4 and ANXA2 binding.Localization of the HE4 protein in ovarian cancer cells
To investigate the localization of HE4 in ovarian cancer
cells, the enhanced green fluorescent protein (EGFP)-
tagged HE4 plasmid was transfected into ES-2 cells. Ob-
servation of the stably transfected cell line ES-2-HE4-H
with high HE4 expression for 5 h showed the translocation
of HE4 protein from the cytoplasm and peri-nuclear re-
gions into the nucleus. Furthermore, secretion of HE4 to
the extracellular regions and its retention on the cell
membrane (the membrane of the ovarian cancer cells
themselves or that of neighboring cells) were also ob-
served (See Additional file 3). The binding of HE4 to cell
membrane proteins may play a decisive role in the malig-
nant biological behavior of ovarian cancer cells and signal
transduction.HE4 and ANXA2 specific binding promotes ovarian cancer
cell invasion and metastasis
To evaluate the effect of the HE4 and ANXA2 interaction
on the invasion and metastasis of ovarian cancer cells, sta-
bly transfected ES-2 and CaoV-3 cells with low ANXA2
expression were generated. The downregulation of
ANXA2 gene and protein expression was confirmed in
the ES-2 and CaoV-3 cells (P <0.05; Figure 4A, B, C). The
results of the scratch test and Transwell assay showed that
interference with ANXA2 significantly reduced the migra-
tion and invasive ability of ovarian cancer cells (P <0.05;
Figure 4D, E, F), and exogenous HE4 active protein sup-
plementation did not significantly restore the migratory
and invasive ability after 12 h (P >0.05).
However, transient transfection of a plasmid with high
ANXA2 expression restored the migration and invasive
ability of cells with low ANXA2 expression and this effect
was enhanced by extrinsic HE4 active protein supplemen-
tation (P <0.05; Figure 4D, E, F), which further validated
that HE4 and ANXA2 binding promotes ovarian cancer
cell invasion and migration.
In vivo studies were performed to analyze the metastasis
of ovarian cancer. An autopsy revealed a large number of
lung metastatic nodules in the ANXA2 high expression
group, whereas almost no metastatic nodules were ob-
served in the low expression groups (Figure 5A). Few
metastatic nodules were detected in the mock groups
(Figure 5A). The results of H&E staining showed that the
mice in all the high expression groups were metastasized,
whereas only 2 mice were metastasized among the mock
groups. There was no metastasis in the low expression
groups during the experiment. The matastasis rates in the
ANXA2 high expression, mock and low expression groups
were 100.00%, 40% and 0%, respectively. The high expres-
sion groups displayed the highest matastasis rates, which
were significantly higher than those of the mock groups
(P < 0.05, Figure 5B). Matastasis rates in the mock groups
were markedly higher than those in the low expression
groups (P < 0.05). The results of immunohistochemistry
were consistent with those of H&E staining (Figure 5C).
The peritoneal metastasis results are all the same as the
results of lung metastasis (Figure 5D). The matastasis rates
in the ANXA2 high expression, mock and low expression
groups were 100.00%, 40% and 0%, respectively (P < 0.05).
The upregulation of annexin II promoted the metastasis
of ovarian cancer, whereas the downregulation of annexin
II decreased metastasis.
HE4 and ANXA2 binding activates the MAPK and FOCAL
adhesion signaling pathways and promotes ovarian
cancer cell invasion and metastasis
To explore the mechanism underlying the effect of HE4
and ANXA2 binding on ovarian cancer cell invasion and
metastasis, gene chip analysis was performed in cells with
Figure 3 (See legend on next page.)
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Figure 3 Effect of HE4 transfection on ANXA2 protein and gene expression. A, The immunoblot shows the expression of HE4 and ANXA2
in ovarian cells after transfection. Lanes 1, 2, 3, 4 and 5: expression of HE4 and ANXA2 before and after HE4 gene transfection in ES-2 cells; lanes
6, 7, 8, 9 and 10: expression of HE4 and ANXA2 before and after HE4 gene transfection in CaoV-3 cells; lanes 1 and 6: high HE4 expression groups
after HE4 gene transfection in the ES-2 and CaoV-3 cell lines, separately; lanes 2, 4, 7 and 9: mock groups; lanes 3 and 8: untreated groups; lanes 5
and 10: HE4 low expression groups after HE4 shRNA transfection in the ES-2 and CaoV-3 cell lines, separately. Quantitative data in panel B are expressed as
HE4 and ANXA2 relative to GAPDH. Real time PCR (C) results show the expression of HE4 and ANXA2 in each group. D, Immunocytochemistry
images show the expression of HE4 and ANXA2 before and after HE4 gene transfection. HE4-H: HE4 high expression after transfection; HE4-L, HE4
low expression after transfection (see Additional file 1). E, Double-labeling immunofluorescence shows the colocalization of HE4 and ANXA2 in ovarian
cancer CaoV-3 cells after HE4 shRNA transfection (original magnification, ×400). The nucleus (blue, A1, A2), ANXA2 (green, B1, B2), HE4 (red, C1, C2) and
merged images (D1, D2) are shown.
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addition, signaling pathway proteins associated with the
migration and invasion of tumor cells were analyzed. Silen-
cing of the HE4 gene significantly downregulated the gene
expression of the MAPK signaling pathway-associated fac-
tor MKNK2 and FOCAL adhesion signaling pathway-
associated factor LAMB2 in CaoV-3 cells (Figure 5E,
P <0.05), whereas extrinsic HE4 protein supplementation
restored the expression of these genes to a level signifi-
cantly higher than that in the blank plasmid group
(P <0.05). Our findings indicated that HE4 and ANXA2
binding activates the MAPK and FOCAL signaling path-
ways, thereby promoting the invasion and metastasis of
ovarian cancer cells.
Expression patterns of HE4 and ANXA2 in ovarian tissue
groups
HE4 was mainly localized in the cell membrane and cyto-
plasm, and detected to a limited extent in the perinuclear
region (Figure 5F). The positive expression rates in malig-
nant, borderline, benign and normal ovarian tissues of
HE4 were 78.00%, 55.56%, 20% and 0%, respectively. Ma-
lignant groups displayed the highest positive expression
and significantly higher than the rate of the borderline
(P = 0.04). Expression rates in borderline groups were
markedly higher than that in benign groups (P = 0.03). No
HE4 expression was detected in normal groups.
ANXA2 was mainly detected in the cell membrane
and cytoplasm (Figure 5F). Expression of ANXA2 was
similar to that of HE4 (generally up to 76.00%), and sig-
nificantly higher than the rate of the borderline (51.85%,
P = 0.03). Differences were significant between the bor-
derline and benign tumor groups (P = 0.04). ANXA2 was
not expressed in the 15 normal ovarian tissue cases
(Table 1).
Correlation of HE4 and ANXA2 expression with clinical
features of ovarian cancer
In ovarian serous and mucinous cystadenocarcinomas,
the positive expression rates of HE4 were 73.33% and
85%, respectively, which were similar (P = 0.53). HE4
was detected in100% of stage III to IV ovarian cancer
cases. The rate of expression was higher than that instages I to II (65.63%, P = 0.01). Expression rates of HE4
in the well, moderate, and poor differentiation groups
were 44.44%, 93.33% and 100%, respectively. The expres-
sion rate in the poor differentiation group was thus
higher than that in well differentiation group (P < 0.01).
The positive rate of HE4 in the lymphatic metastasis
group (100%) was higher than that that of the non-
lymphatic metastasis group (63.33%, P = 0.04) although
there are 8 unknown samples. Some patients underwent
uncompleted lymphadenctomy during the operation.
The positive expression rates of ANXA2 in ovarian
serous and mucinous cystadenocarcinomas were 66.67%
and 90%, respectively. However, the differences between
these expression rates were not significant (P = 0.12).
The ANXA2 was detected in all cases of stage III to IV
ovarian cancer at a higher rate, compared to stages I to
II (65.63%). The expression rates of ANXA2 in the well,
moderate, and poor differentiation groups were 38.89%,
93.33%, and 100%, respectively. Antigen levels were up-
regulated with decreasing differentiation levels. The
positive rate of ANXA2 in the lymphatic metastasis
group was higher than that that of the non-lymphatic
metastasis group (P = 0.03) (Table 2).
Discussion
Serum HE4 detection is widely used for the diagnosis
and monitoring of epithelial ovarian cancer. However,
HE4 is not considered a target for the clinical treatment
of ovarian cancer largely because its role in the develop-
ment and progression of ovarian cancer is unclear. In
the present study, we identified ANXA2 as an HE4 inter-
acting protein using MALDI-TOF-MS, and their binding
interaction was validated using co-immunoprecipitation
and confocal laser scanning microscopy. HE4 and ANXA2
interaction was then validated in three ovarian cancer cell
lines, which suggested that such an interaction is present
in ovarian cancer tissues. In addition, pull-down assays re-
vealed that the HE4 and ANXA2 binding site is located
after the 26th amino acid at the N terminus.
Recent studies showed that HE4 promotes ovarian cancer
cell invasion and metastasis [8,9]. Our previous study vali-
dated this finding (unpublished data); however, the under-
lying mechanisms remained unclear. To further explore the
Figure 4 HE4 and ANXA2 specific binding promotes ovarian cancer cell invasion and migration. A, The immunoblot shows the expression
of HE4 and ANXA2 in ovarian cancer cells after ANXA2 transfection. Lanes 1 and 4: ANXA2 low expression groups in ES-2 and CaoV-3 cells; lanes 2
and 3: mock groups. Quantitative data in panel B are expressed as ANXA2 and HE4 relative to GAPDH. Real time PCR results (C) show the expression of
HE4 and ANXA2 in each group. The migratory (D, E, original magnification × 40) and invasive (F, original magnification × 200) capacities of ovarian
cancer cells before and after transfection and extrinsic HE4 active protein supplementation. Lane 1, mock groups; lane 2, ANXA2 low expression groups;
lane 3, ANXA2 low expression cells treated with HE4 active protein; lane 4, ANXA2 high expression groups; lane 5, ANXA2 high expression cells treated
with HE4 active protein; lane 6, antibody-mediated blocking of annexin II; lane 7, antibody-mediated blocking of ANXA2 expression with HE4 active
protein treatment.
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and metastasis of ovarian cancer cells after its secretion to
the extracellular medium, EGFP-transfected ES-2 cells weredynamically observed for 5 h. The results showed that the
HE4 protein was not only expressed in the cytoplasm and
peri-nuclear regions of ES-2 cells, but also in the nucleus.
Figure 5 (See legend on next page.)
Zhuang et al. Molecular Cancer 2014, 13:243 Page 8 of 14
http://www.molecular-cancer.com/content/13/1/243
(See figure on previous page.)
Figure 5 Expression Patterns of HE4 and ANXA2 in ovarian tissues. A, Cells at a density of 1 × 106 in 200 μl were injected into nude mice
through the tail vein. Macroscopic view of lung metastatic nodes after inoculation with cancer cells. B, H&E staining in lung tissues of
nude mice. High expression (a, original magnification × 200), low expression (b), and mock (c) groups are shown. C, Immunohistochemical
staining of lung tissues of nude mice. High expression (a1, a2; original magnification × 200), low expression (b1, b2), and mock (c1, c2)
groups are shown. D, Representative images of the peritoneal metastasis results. High expression (a), low expression (b), and mock (c)
groups are shown. E, Real time PCR results show the expression of MKNK2 and LAMB2 in ovarian cancer CaoV-3 cells. Lane 1, mock group; lane 2, HE4
low expression groups; lane 3, HE4 low expression cells treated with HE4 active protein; lane 4, HE4 high expression groups. F, Immunohistochemical
staining of ovarian malignant tumors (serous tumors, 1 and 2; mucinous tumors, 3 and 4; borderline tumors, 5 and 6; benign tumors, 7 and 8); and
normal ovarian tissues, 9 and 10). HE4 (1, 3, 5, 7 and 9) and ANXA2 (2, 4, 6, 8 and 10; original magnification × 200).
Zhuang et al. Molecular Cancer 2014, 13:243 Page 9 of 14
http://www.molecular-cancer.com/content/13/1/243Furthermore, HE4 secreted to the extracellular region
bound to the membrane of the ES-2 cells themselves and
to that of neighboring cells. The binding of HE4 to cell
membrane proteins may play a decisive role in the malig-
nant biological behaviors of ovarian cancer cells, such as in-
vasion and metastasis.
ANXA2 is a calcium-dependent phospholipid binding
protein that is mainly located on the cell membrane.
ANXA2 is an S100 protein family member and a fibrino-
lytic receptor for the S100A4 protein [11]; annexin II is
a membrane protein. The ANXA2 and S100A4 interaction
can promote tissue-type plasminogen activator (t-PA)-
dependent plasmin generation and activation of its down-
stream matrix metalloproteinases (MMPs), including that
of matrix metalloproteinase-2 (MMP-2). This results in
extracellular matrix (ECM) remodeling and neovasculari-
zation, which promote the invasion and metastasis of
tumor cells [12-14]. Changes in the expression and spatial
distribution of ANXA2 are closely associated with the in-
vasion and metastasis of multiple tumors, and the inter-
action between ANXA2 and molecules involved in tumor
invasion and metastasis may promote these malignant be-
haviors. The present study is the first to demonstrate the
structural relationship between HE4 and ANXA2, which
led to the hypothesis that HE4 and ANXA2 binding pro-
motes ovarian cancer cell invasion and metastasis. To test
this hypothesis, we generated ovarian cancer cell lines with
high and low HE4 expression and showed that the up- or
downregulation of HE4 was accompanied by parallel
changes in ANXA2 expression in the treated cell lines.Table 1 The Expression of HE4 and ANXA2 in Different Ovaria
Groups Cases HE4
- + ++ +++ Positive cases Positive
Malignant 50 11 6 16 17 39 78.0
Mucinous 20 3 4 6 7 17 85.
serous 30 8 2 10 10 22 73.
Borderline 27 12 5 6 4 15 55.5
Benign 15 12 3 0 0 3 2
Normal 15 15 0 0 0 0 0
*Compared with the borderline group. P = 0.04.
**Compared with the benign group. P = 0.03.
#Compared with the borderline group. P = 0.03.
##Compared with benign group. P = 0.04.Interference with HE4 significantly inhibited HE4 and
ANXA2 co-localization on the cell membrane, as shown
by confocal laser scanning microscopy. In addition, the re-
duction in the invasive and metastatic abilities of cancer
cells induced by ANXA2 downregulation were not re-
versed by HE4 active protein supplementation, whereas
upregulation of ANXA2 expression restored invasion and
migration and this effect was enhanced by exogenous HE4
active protein. These results indicated that ANXA2 may
act cooperatively with HE4 in promoting the invasion and
migration of ovarian cancer cells. Immunohistochemical
analysis of clinical specimens showed that HE4 and
ANXA2 protein expression levels were higher in malig-
nant and borderline epithelial ovarian tissues than in be-
nign epithelial ovarian tumor tissues. In addition, the two
proteins were expressed at higher levels in ovarian cancer
tissues with lymph node metastasis than in those without
(all P < 0.05). The histological results confirmed the associ-
ation of HE4 and ANXA2 expression with the degree of
malignancy of ovarian cancer.
Recent studies showed that upregulation of ANXA2
expression activates the MAPK signaling pathway and
promotes the malignant biological behaviors of tumor
cells, such as proliferation [15], invasion and metastasis
[16,17]. Serial analysis of gene expression showed that
upregulation of ANXA2 activates RPS6KA1, a down-
stream component of the MAPK signaling pathway,
thereby affecting the development and progression of
gallbladder cancer [18]. In addition, HE4 was found to
promote the invasion and metastasis of ovarian cancern Tissues
ANXA2
rate (%) - + ++ +++ Positive cases Positive rate (%)
0* 12 5 19 14 38 76.00#
00 2 4 10 4 18 90.00
33 10 1 9 10 20 66.67
6** 13 5 6 3 14 51.85##
0 12 2 1 0 3 20
15 0 0 0 0 0
Table 2 Association between HE4 and ANXA2 Expression and Pathological Features
Features Cases HE4 ANXA2
Positive cases Positive rate (%) P Positive cases Positive rate (%) P
Pathological type
Mucinous 20 17 85.00 =0.53 18 90.00 =0.12
Serous 30 22 73.33 20 66.67
FIGO stage
I-II 32 21 65.63 = 0.01 21 65.63 = 0.05
III-IV 18 18 100.00 17 94.44
Differentiation
Well 18 8 44.44 = 0.003* <0.01** 7 38.89 = 0.003# <0.01##
Moderate 15 14 93.33 14 93.33
Poor 17 17 100.00 17 100.00
Lymphatic metastasis
No 30 19 63.33 = 0.04 18 60.00 =0.03
Yes 12 12 100.00 12 100.00
Unknown 8 8 8
*Compared the well- with moderate-differentiation groups.
**Compared the well- with poor-differentiation groups.
#Compared the well- with moderate-differentiation groups.
##Compared the well- with poor-differentiation groups.
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dicated that MAP kinase interacting serine/threonine
kinase 2 (MKNK2) and laminin beta 2 (LAMB2) gene
expression levels were downregulated in response to
HE4 interference in ovarian cancer cells, whereas ex-
ogenous HE4 protein supplementation reversed this ef-
fect. Our results suggest that HE4 and ANXA2 binding
activates the MAPK and FOCAL adhesion signaling
pathways, thereby promoting the invasion and metasta-
sis of ovarian cancer cells. Our results indicate that
annexin II may help HE4 translocate into the nucleus,
where it functions as a transcription factor promoting
the expression of MAPK or FOCAL signaling molecules.
Tumor invasion and metastasis are complex patho-
physiological processes that include not only interactions
between tumor cells and between tumor cells and host
cells, but also a complex regulatory network involving
multiple bioactive molecules. A recent study showed
that binding of HE4 to MMP2 and MMP9 in renal cells
promotes renal fibrosis [19]. ANXA2 was shown to pro-
mote the invasion and metastasis of ovarian cancer cells
through the activation of MMP2 [12-14]. These findings
together with those of our previous studies suggest that
HE4 is secreted to the extracellular medium, where it
binds to ANXA2 on the cell membrane, activating
downstream signaling molecules and inducing changes n
the cell nucleus. Furthermore, the HE4 and ANXA2 com-
plex may promote the invasion and metastasis of ovarian
cancer cells by activating MMPs and promoting ECM re-
modeling. S100A4 and ANXA2 binding promotes invasionand signal transduction in tumor cells [11]. Further studies
are necessary to investigate the role of S100A4 in the inter-
action between HE4 and ANXA2 in ovarian cancer cells.
Elucidation of the biological functions of HE4 will reveal
the mechanisms underlying the role of HE4 in the develop-
ment, invasion and metastasis of ovarian cancer and may
lead to the design of therapeutic strategies targeting HE4
and ANXA2 for the treatment of ovarian cancer.
Conclusions
In the present study, we showed that annexin II is an
HE4 interacting protein. The binding interaction be-
tween HE4 and annexin II promoted ovarian cancer cell
invasion and metastasis by activating the MAPK and
FOCAL adhesion signaling pathways. Elucidation of the
biological functions of HE4 will reveal the mechanisms
underlying the role of HE4 in the development, invasion
and metastasis of ovarian cancer and may lead to the de-
sign of therapeutic strategies targeting HE4 and ANXA2
for the treatment of ovarian cancer.
Methods
Construction of expression vectors
Reverse transcription-PCR products produced from hu-
man cDNA and corresponding to full-length human
HE4 and annexin II were cloned in pGEX-4 T or pGEX-
6 T vectors (Amersham Biosciences). N-terminal trun-
cated forms of annexin II with its first 15 or 26 amino
acids deleted, A2-del15 and A2-del26, respectively, for
GST pull-down assays. Glutathione S-transferase fusion
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beads and cleaved with thrombin or PreScission protease
to remove glutathione S-transferase tag according to the
manufacturer’s instructions (Amersham Biosciences). An
HE4 expression construct was generated by subcloning
PCR-amplified full-length human HE4 cDNA into the
pEGFP-N1 or pCMV6 plasmid. The following primers
are used: P1:5’- TCC GCT CGA GAT GCC TGC TTG
TCG CCT AG -3’和P2:5’- ATG GGG TAC CGT GAA
ATT GGG AGT GAC ACA GG -3’. Two shRNA ex-
pression vectors for human HE4 were constructed using
the vector pSilence. The mRNA target sequences chosen
for designing HE4-shRNA are GTC CTG TGT CAC
TCC CAA T for HE4-shRNA1 and GAT GAA ATG
CTG CCG CAA T for HE4-shRNA2. Two shRNA ex-
pression vectors for human ANXA2 were constructed
using the vector pSilence. The mRNA target sequences
chosen for designing ANXA2-shRNA are GTA CTA
TTA TAT CCA GCA A for ANXA2-shRNA1 and AGG
AAA TTA ACA GAG TCT A for ANXA2-shRNA2.
Cell culture and transfection
OVCAR-3,SKOV-3,ES-2 and CaoV-3 ovarian cancer cell
lines were purchased from American Type Culture Collec-
tion and propagated in McCoy’s 5A modified medium
with 10% fetal bovine serum. Transfection was carried out
using liposomes with a vector transfection kit accord-
ing to the instructions. Stable cell lines expressing HE4
and ANXA2 shRNAs were selected for 14 days with
800 ug/ml G418 (Invitrogen).
Immunoprecipitation, silver staining, and protein
identification by mass spectrometry
OVCAR-3 cell was immunoprecipitated using an anti-
HE4 antibody (Santa Cruz, goat, CA) and combined with
30 ul of protein A/G PLUS agarose (Santa Cruz) by rotat-
ing for 1 h at 4°C. The eluents were loaded onto SDS-
PAGE gel and Coomassie brilliant blue-stained. The
expressed bands were excised and processed for in-gel
trypsin digestion and subjected to MALDI-TOF-MS ana-
lysis. Anti-HE4 antibody was replaced by goat IgG (Bioss,
China) for negative control. The peptide and proteins were
identified from the MS/MS spectra using the MASCOT
algorithm (Matrix Science, Boston, MA). Peptide mass fin-
gerprinting was carried out using the MASCOT search en-
gine from GPS Explorer software (Applied Biosystems,
Foster City, CA). Mass spectra used for manual denovo
sequencing were annotated with the Data Explorer soft-
ware (Applied Biosystems).
Co-immunoprecipitation and Western Blot
Ice-cold RIPA buffer (1 ml) was added to ovarian cancer
cells, followed by incubation at 4°C for 30 min. After cen-
trifugation at 15,000 × g for 30 min at 4°C, supernatantfractions were collected and treated with anti-HE4 anti-
body (10 μl) (Santa Cruz, goat polyclonal) or anti-annexin
II (Proteintech, mouse monoclonal) for 3 h at 4°C. Protein
A/G PLUS-Agarose (20 μl; Santa Cruz)was added, followed
by incubation on a rocker platform overnight at 4°C. The
procedure was followed as described previously [20]. The
negative control contained only 10 μl HE4 or ANXA2 anti-
body without protein. Immunoprecipitates were subse-
quently subjected to 12% SDS gel electrophoresis and
analyzed via Western blot using HE4 monoclonal (Abcam,
Rabbit) and annexin II monoclonal (Abcam, Mouse) anti-
bodies. Proteins were visualized using ECL reagent
(Amersham ECL Prime detection). Experiments were
repeated three times.
Cytoplasmic and membrane proteins extraction
Cytoplasmic and membrane proteins were extracted ac-
cording to the instructions of the membrane and cytoplas-
mic protein extraction kit (Beyotime, Haimen, China).
Membrane protein extraction reagent A (1 ml) was added
to 5 × 107 cells, followed by incubation at 4°C for 15 min.
After centrifugation at 700 g for 10 min at 4°C, super-
natant fractions were collected carefully and kept as cyto-
plasmic proteins. The precipitate was centrifugated at
14,000 × g for 30 min at 4°C. Then, membrane protein ex-
traction reagent B (300 ul) was added after the super-
natant fractions were discarded, and the mix was vortexed
violently for 5 sec followed by incubation at 4°C for
15 min. These steps were repeated twice. After centrifuga-
tion at 14,000 × g for 5 min at 4°C, supernatant fractions
were collected carefully and kept as membrane proteins.
Pull-down assay
Bacterial lysate expressing His-tagged ANXA2 protein was
purified using HisTrap Kit (Amersham Biosciences). Puri-
fied His-tagged ANXA2 was incubated with GST-HE4
immobilized on 100ul of glutathione-Sepharose beads (GE
Healthcare). Beads were extensively washed with Buffer A
(20 m M Tris–HCl (pH 8.0), 1 mM EDTA, 1 mM dithio-
threitol, 150 mM NaCl, 1% Triton X-100) containing 1ul
protease inhibitor mixture. The bound proteins were eluted
by boiling in the SDS sample buffer for 10 min and immu-
noblotted with an anti-His-tagged antibody (GeneTex).
Sandwich ELISA
Ninety- six-well polystyrene microplates were coated
with a capture antibody against HE4 (Santa Cruz, goat
polyclonal) at 5 μg/ml in coating buffer at 4°C for 16 h.
After blocking with 5% BSA, 100 μl of the cell superna-
tants were added to the wells and incubated at room
temperature for 2 h followed by peroxidase-labeled anti-
goat IgG antibody. Color reaction was developed with o-
phenylenediamine dihydrochloride solution at room
temperature for 20 min. The reaction was stopped with
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with 1% BSA instead of the mAbs. The optical density of
each well was determined within 30 min using a micro-
plate reader at 450 nm [21].
Immunohistochemistry and immunocytochemistry
Histological section of each group of ovarian tissue was
5 μm. Each tissue had two serial sections. Expression pat-
terns of HE4 and ANXA2 in ovarian carcinoma tissues
were analyzed via immunohistochemical streptavidin-
peroxidase staining. Positive and negative immunohisto-
chemistry controls were routinely employed. Normal
epididymis tissue served as a positive control for HE4,
while breast cancer tissue was used as the positive control
for ANXA2 antigen. The negative control was incubated
with rabbit IgG (Bioss, China) instead of primary antibody.
The working concentrations of primary antibodies against
HE4 and ANXA2 used were 1:40 (Abcam, Rabbit poly-
clonal to HE4) and 1:1200 (Abcam, Rabbit polyclonal to
ANXA2), respectively. The empirical procedure was per-
formed based on the manufacturer's instructions.
Cells at exponential phase of growth were digested by
0.25% trypsin and cultured in medium containing 10%
FBS to prepare single-cell suspension. Cells were washed
twice with cold PBS when growing in a single layer, and
fixed with 4% para- formaldehyde for 30 min. The ex-
pression of annexin II and HE4 on cells were detected
according to the SABC kit instructions. The working con-
centrations of primary antibodies against HE4 and ANXA2
used were 1:300 (Abcam) and 1:1000 (Abcam), respect-
ively. The primary antibody was replaced by rabbit IgG for
negative control. The average optical densities were mea-
sured under a microscope with image processing, being
presented as the means ± standard deviation for three
separate experiments.
Double-labeling immunofluorescence method
Cells at exponential phase of growth were digested by
0.25% trypsin and cultured in medium containing 10%
FBS to prepare single-cell suspension. Cells were washed
twice with cold PBS when growing in a single layer, and
fixed with 4% para- formaldehyde for 30 min. The cells
were simultaneously incubated with primary antibodies
against HE4 (1:100, Abcam, Rabbit) and annexin II (1:50,
Proteintech, Mouse). The primary antibody was replaced
by rabbit or mouse IgG for negative control. The working
concentrations of fluorescein isothiocyanate and TRITC
were 1:100. Nuclei were counterstained with DAPI. The
empirical procedure was performed according to the man-
ufacturer's instructions.
Scratch test and the transwell assay
Scratch test: Cells during the log phase were selected
and single cell suspensions were prepared. Cells on a 6well plate were cultured until 90% density. And then the
plate was scratched with a 200ul pipette tip. Cells were
cultured in medium without serum. After 12 h, the
width of the scarification were observed under micro-
scope. Transwell assay: The Matrigel were melted and
put at 4°C refrigerator overnight the day before this ex-
periment. The pipette tip was pre-cooled in ice-cold for
0.5 h during experiment, and the ECM gel was diluted
by 1:8 with serum free medium, Matrigel 100 ul was
added into the upper chambers, the whole process was
performed on ice. Then they were placed in an incubator
at 37°C for 5 h. 105/mL cells in logarithmic growth
phase was added in each well for 200 ul, 500 ul medium
supplemented with 10% fetal bovine serum were added
in lower chamber. After culturing for 24 h, nutrient so-
lution was abandoned and a cotton swab was used to
gently wipe out the upper layer of transwell. Membrane
of transwell was fixed with methanol for 20 min, washed
with PBS 3 times, then staining with 0.1% crystal violet
for 20 min after airing. The invasive cell numbers of 5
fields (upper and lower, left and right, middle) were
counted under microscope, the mean value was obtained
and the statistical analysis was made. The cells of each
group were treated in triplicate and experiments were
repeated three times.
Antibody blocking tests
Cells during the log phase were selected and single cell
suspensions were prepared. Anxa2 mAb (10 μg/ml) was
added to the adherent cells. Mouse IgG isotype control
and PBS blank control groups were generated. The cells
were incubated at 37°C for 30 min. The experiments
were repeated three times and the average value was cal-
culated. In the Transwell assay, Anxa2 mAb (10 μg/ml)
was added into the upper chamber while paving the
cells. The cells of each group were treated in triplicate
and experiments were repeated three times.
Transgenic mice and tail-vein injections
Female BALB/c nu/nu mice (4–6-weeks-old; Shanghai In-
stitute of Material Medicine, Chinese Academy of Science)
were raised in specific pathogen-free conditions. All ex-
perimental protocols were approved by the Committee for
the Care and Use of Laboratory Animals of Shengjing
Hospital Affiliated with China Medical University., the
permit numbers is 2014PS163K.
Tail-vein injection experiments and peritoneal metas-
tasis assays were performed on nu/nu mice obtained as
described elsewhere [22]. The 30 mice were divided into
three groups randomly, namely ANXA2 high expression,
ANXA2 low expression and mock groups. Cells at the
exponential phase of growth were digested by 0.25%
trypsin and resuspended in PBS. A volume of 200 μl
(1 × 106) was injected into the tail-vein of nu/nu mice
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cells/200 μl PBS) were injected intraperitoneally for peri-
toneal metastatic formation and the mice were observed
for 25 days. The mice were then killed humanely and an
autopsy was performed and the lungs and the peritoneal
were examined for tumours separately. Then, tissues
were dehydrated, processed, and embedded in paraffin
wax. Serial sections 5-μm thick were prepared from each
block, stained with haematoxylin and eosin (H&E) and
analyzed by immunohistochemistry (HE4 antibody,
1:3000; ANXA2, 1:4000).
Time lapse observation
Cells during the log phase were selected and single cell
suspensions were prepared. Cells on a Confocal dish
were cultured until 60% density. And then observe the
cells using confocal microscope (Nikon A1) in 5%CO2,
37°C for 5 h. Continuous shooting at every 5 minutes.
The experiments were repeated three times (see supple-
mentary material).
Ethics statement
Samples were fully encoded to protect patient confiden-
tially. The study and its protocols were approved by the
Research Ethics committees of Shengjing Hospital Affiliated
with China Medical University. IACUC permit number is
2013PS23K. Because all the samples used in the study were
discarded, the informed consents were not needed. And the
ethics committees approved this.
Patients and tissue samples
Selected paraffin samples (107 in total) were obtained
from the operations performed from 2004 to 2012 in the
Department of Gynecology and Obstetrics of our hos-
pital. All tissue sections were examined by specialists to
obtain a final diagnosis. Normal ovarian samples were
obtained from tissue excised in cervical cancer opera-
tions. Among the benign ovarian tumors, six cases were
mucinous cystadenoma, nine cases were serous cystade-
noma. There were 27 cases of borderline ovarian tumors
(including 13 mucinous and 14 serous cystadenomas).
The mean age of these patients was 46.97 years (16–81
years). The age range of the ovarian cancer group was
16 to 73 years; median age was 53 years. The age range
of the borderline ovarian tumor group was 22 to
77 years; median age was 36 years. The age ranges of the
benign ovarian tumor and normal tissue groups were 22
to 81 years and 37 to 59 years, respectively; median ages
were 44 and 50.5 years, respectively. Comparing these
groups, there is no statistical significance (P > 0.05). Spe-
cific histological types and pathological grades are pre-
sented in Tables 1 and 2.
All cases were primary, and the information was
complete. All the patients had received a Gastroscopyor colposcopy to exclude other primaries. Patients were
not subjected to chemotherapy prior to the operation.
Assessment standard
Immunohistochemistry
We consider a positive result if there are buffy granules
in the cell membrane and cytoplasm. According to the
chromatosis intensity, no pigmentation, light yellow,
buffy, and brown are scored 0, 1, 2, and 3, respectively.
We choose 5 high-power fields in series from each slice,
then score them and take the mean percentage of the
chromatosis cells: chromatosis cells that account less
than 5% are 0, 5% to 25%; 1, 26% to 50%; 2, 51% to 75%;
3, and greater than 75%; 4, Multiply these 2 numbers; 0
to 2 is considered (−); 3 to 4, (+); 5 to 8, (++); and 9 to
12, (+++). Two observers read the sections to control
error. At the same time, we use the NIS-Elements BR
2.10 picture analysis software of the Japanese Nikon
Company (Tokyo, Japan) to measure the mean optical
density (MOD).
Statistical analysis
SPSS version 17.0 (SPSS Inc, Chicago, IL) software was
used for statistical analysis. χ2 analysis, variance analysis,
and t-test were employed. P < 0.05 was considered statisti-
cally significant.
Additional files
Additional file 1: An additional table shows this in more detail. The
level of HE4 secretion prior and post stable over expression in CaoV-3
cancer cell lines in an ELISA experiment.
Additional file 2: An additional table shows this in more detail. The
integral optical density on immunocytochemical staining with anti-HE4
and anti-ANXA2 antibody in the cell lines before and after transfection.
Additional file 3: An additional movie file shows this in more detail.
Time lapse observation of ovarian cancer cell which contain EGFP tag
using confocal microscope (Nikon A1) in 5%CO2, 37°C for 5 h.
Continuous shooting at every 5 minutes.
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